Dr. Maraganore brings a wealth of experience and knowledge in the field of RNA therapeutics. He is known for his remarkable contributions while serving as the founding CEO of Alnylam from 2002 to 2021. At Alnylam, Dr. Maraganore led the company from early platform research on RNA interference through clinical development to global approval and commercialization of the first RNAi therapeutic medicines including, ONPATTRO®, GIVLAARI®, OXLUMO®, and AMVUTTRA®. His leadership has been instrumental in changing the genetic medicine landscape with groundbreaking RNAi-based therapeutics that are helping patients today.

Dr. Maraganore currently serves as a Venture Partner at ARCH Venture Partners and Atlas Ventures, an Executive Partner to RTW Investments, a Senior Advisor at Blackstone Life Sciences and is principal of JMM Innovation LLC. He previously served as Chair of the Biotechnology Innovation Organization (BIO) and currently serves on the Board of several public and private companies.